News Anti-LINGO-1: All You Need to Know Anti-LINGO-1: All You Need to Know by admin | January 19, 2016 Share this article: Share article via email Copy article link Recently, Biogen released results from its Phase 2 acute optic neuritis (AON) RENEW trial which tested Anti-LINGO-1. Learn more about this results here. So what isĀ Anti-LINGO-1? According to the MS Society,Ā Anti-LINGO-1 (also known as BIIB033) is a treatment in development by the pharmaceutical company Biogen which is currently being tested in people with optic neuritis, relapsing-remitting MS, and secondary progressive MS. LINGO is a protein found in nerve cells and myelin-making cells called oligodendrocytes. Blocking the activity of this protein with an antibody called anti-LINGO-1 has been shown to result in myelin repair in animal models of MS. Anti-LINGO-1 itās taken as an intravenous infusion. Read the Anti-LINGO-1 latest news here:Ā https://bit.ly/1ZJzxrV Print This Page Tags ANTI-LINGO-1, Biogen, MS Society, optic neuritis, relapsing-remitting MS, RRMS, secondary progressive MS, SPMS
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year
April 22, 2024 News by Margarida Maia, PhD Viatris launches low-dose Copaxone generic formulation in Canada
April 22, 2024 News by Marisa Wexler, MS AAN 2024: Briumvi found to ease disability in certain MS patients